Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
49.97
-0.03 (-0.06%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Tarsus Pharmaceuticals stock have an average target of 63.67, with a low estimate of 41 and a high estimate of 78. The average target predicts an increase of 27.42% from the current stock price of 49.97.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 6, 2025.
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $54 → $58 | Strong Buy | Maintains | $54 → $58 | +16.07% | Mar 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $75 → $78 | Strong Buy | Maintains | $75 → $78 | +56.09% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +46.09% | Feb 26, 2025 |
| Barclays | Barclays | Buy Maintains $62 → $60 | Buy | Maintains | $62 → $60 | +20.07% | Feb 26, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 24, 2025 |
Financial Forecast
Revenue This Year
372.64M
from 182.95M
Increased by 103.68%
Revenue Next Year
543.04M
from 372.64M
Increased by 45.73%
EPS This Year
-1.57
from -3.07
EPS Next Year
1.32
from -1.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 400.7M | 597.7M | 792.8M | ||
| Avg | 372.6M | 543.0M | 722.7M | ||
| Low | 332.0M | 486.0M | 657.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 119.0% | 60.4% | 46.0% | ||
| Avg | 103.7% | 45.7% | 33.1% | ||
| Low | 81.5% | 30.4% | 21.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.19 | 2.06 | 6.96 | ||
| Avg | -1.57 | 1.32 | 4.29 | ||
| Low | -1.98 | 0.70 | 2.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 427.6% | ||
| Avg | - | - | 225.5% | ||
| Low | - | - | 88.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.